Search
01/08/2021
Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab
Lambert, J, Hansen, JB, Sohrt, A, Puig, L. Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab. Dermatology and Therapy. 2021; 11(4)DOI:10.1007/s13555-021-00545-5. PMID:33988818. IF:3.661(Q2/3D).
01/08/2021
Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: A Machine Learning Predictive Model
Papp, KA, Soliman, AM, Done, N, Carley, C, Wirtz, EL, Puig, L. Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: A Machine Learning Predictive Model. Dermatology and Therapy. 2021; 11(4)DOI:10.1007/s13555-021-00550-8. PMID:34019229. IF:3.661(Q2/3D).
01/07/2021
Janus Kinase Inhibitors in Dermatology: Part 2: Applications in Psoriasis, Atopic Dermatitis, and Other Dermatoses
Garcia-Melendo, C, Cubiro, X, Puig, L. Janus Kinase Inhibitors in Dermatology: Part 2: Applications in Psoriasis, Atopic Dermatitis, and Other Dermatoses. Actas Dermo-Sifiliograficas. 2021; 112(7)DOI:10.1016/j.ad.2020.12.006. PMID:34030992. IF:(Q/D).
01/07/2021
From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment
Vidal, S, Puig, L, Carrascosa-Carrillo, JM, Gonzalez-Cantero, A, Ruiz-Carrascosa, JC, Velasco-Pastor, AM. From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2021; 22(13)DOI:10.3390/ijms22136740. PMID:34201664. IF:6.208(Q1/3D).